Copyright
©The Author(s) 2015. Published by Baishideng Publishing Group Inc. All rights reserved.
World J Gastroenterol. Jul 14, 2015; 21(26): 8096-8102
Published online Jul 14, 2015. doi: 10.3748/wjg.v21.i26.8096
Published online Jul 14, 2015. doi: 10.3748/wjg.v21.i26.8096
Increased serum soluble lectin-like oxidized low-density lipoprotein receptor-1 levels in patients with biopsy-proven nonalcoholic fatty liver disease
Oguzhan Ozturk, Yasar Colak, Ebubekir Senates, Celal Ulasoglu, Levent Doganay, Ilyas Tuncer, Department of Gastroenterology, Goztepe Teaching and Research Hospital, Istanbul Medeniyet University, 34730 Istanbul, Turkey
Yusuf Yilmaz, Department of Gastroenterology, Marmara University School of Medicine, Istanbul, Turkey and Institute of Gastroenterology, Marmara University, 34854 Istanbul, Turkey
Seyma Ozkanli, Department of Pathology, Goztepe Teaching and Research Hospital, Istanbul Medeniyet University, 34730 Istanbul, Turkey
Yasemin Musteri Oltulu, Ender Coskunpinar, Department of Molecular Medicine, Institute of Experimental Medicine Research, Istanbul University, 34093 Istanbul, Turkey
Author contributions: Ozturk O, Colak Y and Yilmaz Y designed the study; Oltulu YM, Coskunpinar E and Ozkanli S performed the experiments; Doganay L and Senates E interpreted the data and performed the statistical analysis; Ozturk O, Colak Y and Ulasoglu C wrote the manuscript; and Ozturk O, Senates E and Tuncer I made substantial contributions to the discussion of the results.
Institutional review board statement: The study was reviewed and approved by Istanbul Medeniyet University Goztepe Education and Research Hospital Institutional Review Board (document No.: 8-B/28.12.2010) and written informed consent was obtained from all participants.
Informed consent statement: All study participants, or their legal guardian, provided informed written consent prior to study enrollment.
Conflict-of-interest statement: The authors do not have any conflict of interest.
Data sharing statement: No additional data are available.
Open-Access: This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
Correspondence to: Oguzhan Ozturk, MD, Assistant Professor, Department of Gastroenterology, Goztepe Education and Research Hospital, Istanbul Medeniyet University, Doctor Erkin street., Kadikoy, 34730 Istanbul, Turkey. droguzozturk@hotmail.com
Telephone: +90-216-5664000 Fax: +90-216-5664023
Received: February 1, 2015
Peer-review started: February 1, 2015
First decision: March 10, 2015
Revised: April 2, 2015
Accepted: May 7, 2015
Article in press: May 7, 2015
Published online: July 14, 2015
Peer-review started: February 1, 2015
First decision: March 10, 2015
Revised: April 2, 2015
Accepted: May 7, 2015
Article in press: May 7, 2015
Published online: July 14, 2015
Core Tip
Core tip: Lipoprotein receptor-1 (LOX-1) is a biomarker that has been demonstrated to be related to atherosclerosis, insulin resistance, obesity and diabetes. Nonalcoholic fatty liver disease (NAFLD) is the hepatic manifestation of metabolic syndrome. To date, no studies have investigated the association between serum LOX-1 and liver inflammation in biopsy-proven NAFLD patients. In this study, we have shown that the serum LOX-1 levels are correlated with the NAFLD histology scores, which might decrease the need for performing liver biopsy in NAFLD patients.